Price
No data yet.
Social Signal Score
Revenue
$50.53M+31.31%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mihael H. Polymeropoulos
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 533
- Beta
- 0.64
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.33
Financials
Revenue
$50.53M+31.3%Net Income
$-62.51MEBITDA
$-63.25M-2620.8%Free Cash Flow
$-81.70M-12825.7%EPS (diluted)
$-1.04Shares Outstanding (diluted)
60.23M+38.4%Operating Expenses
$108.79MCash & Debt
$170.03MRevenue by Segment (annual)
$188.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $216.10M | $-220.47M | $-3.74 |
| 2024 | $198.77M | $-18.90M | $-0.32 |
| 2023 | $192.64M | $2.51M | $0.04 |
| 2022 | $254.38M | $6.28M | $0.11 |
| 2021 | $268.68M | $33.15M | $0.60 |
| 2020 | $248.17M | $23.34M | $0.43 |
| 2019 | $227.19M | $115.55M | $2.17 |
| 2018 | $193.12M | $25.21M | $0.50 |
| 2017 | $165.08M | $-15.57M | $-0.35 |
| 2016 | $146.02M | $-18.01M | $-0.41 |
| 2015 | $109.92M | $-39.87M | $-0.94 |
| 2014 | $50.16M | $20.19M | $0.58 |
| 2013 | $33.88M | $-20.25M | $-0.67 |
| 2012 | $32.73M | $-27.66M | $-0.98 |
Valuation
VNDAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+15.38%Social Signal Score
Mentions (2)
- Newsprnewswire.com·6h ago·Neutral
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026: The Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026.
View source ↗ - Newsprnewswire.com·9d ago·Negative
… for the Treatment of Generalized Pustular Psoriasis by the European Commission WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, …
View source ↗
Earnings
Wed, Nov 4(in 2 months)
Consensus estimate $-0.72 per share
Typical surprise -22.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.04 vs $-0.58miss
- Wed, May 6$-0.82 vs $-0.53miss
- Wed, Feb 11$-2.39 vs $-2.18miss
- Wed, Oct 29$-0.38 vs $-0.31miss
- Thu, Jul 31$-0.46 vs $-0.34miss
- Wed, May 7$-0.50 vs $-0.55beat
Estimates and results for VNDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VNDA officers and directors.
- Bought
- $514k
- Sold
- $3.4m
15 trades
20 trades
- Williams Timothysold
- Moran Kevin Patricksold
- Wijkstrom Joakimsold
- Polymeropoulos Mihael Hristossold
- Birznieks Gunthersold
- Honore Tagesold
- Polymeropoulos Mihael Hristosbought
- Mitchell Stephen Raysold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.